H. Lundbeck A/S (Lundbeck) reports revenue of DKK 3,563 million for the third quarter of 2012, excluding Lexapro® in the US, an increase of 2% compared to the same period last year. EBITDA and EBIT were DKK 846 million and DKK 661 million respectively, corresponding to an EBITDA margin of 23.4% and an EBIT margin of 18.2%. Profits were affected by the increase in launch costs associated with Lundbeck’s newer products, as well as the loss of revenue from Lexapro due to generic competition.
Distribution of revenue
|DKK million||Q3 2012||Q3 2011||Growth||
|USA (excl. Lexapro)||593||411||44%||28%|
*New Products include Xenazine, Sabril, Sycrest, Lexapro (Japan), Onfi and Treanda
In connection with the third quarter report, Lundbeck’s President and CEO Ulf Wiinberg said:
“We are now one step closer to the launch of our novel antidepressant, vortioxetine, following the filing in Europe, Canada and the very important US market. I am also very pleased with the strategic progress of our new product launches and our geographic expansion.”